Learning from past failures: Challenges with monoclonal antibody therapies for COVID-19.

ABSTRACT: COVID-19, the disease caused by infection with SARS-CoV-2, requires urgent development of therapeutic interventions. Due to their safety, specificity, and potential for rapid advancement into the clinic, monoclonal antibodies (mAbs) represent a highly promising class of antiviral or anti-inflammatory agents. Herein, by analyzing prior efforts to advance antiviral mAbs for other acute respiratory infections (ARIs), we highlight the challenges faced by mAb-based immunotherapies for COVID-19. We present evidence supporting early intervention immediately following a positive diagnosis via inhaled delivery of mAbs with vibrating mesh nebulizers as a promising approach for the treatment of COVID-19.

SUBMITTER: Lai SK 

PROVIDER: S-EPMC7836766 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature